NKTX · Nkarta Therapeutics

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

1150 Veterans Boulevard, South San Francisco, CA, 94080, United States
Biotechnology
Healthcare

Market Cap

80.22M

52 Wk Range

$1.10 - $3.72

Previous Close

$1.12

Open

$1.11

Volume

903,746

Day Range

$1.11 - $1.22

Enterprise Value

-2.202M

Cash

156.6M

Avg Qtr Burn

-25.84M

Insider Ownership

4.87%

Institutional Own.

82.51%

Qtr Updated

Sep 30th 2026